Corporate Profile
Zura Bio is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders. Currently, Zura Bio is developing three assets which have completed Phase 1/1b studies and are Phase 2 ready. The company is developing a portfolio of therapeutic indications for ZB-106 (tibulizumab), ZB-168, and ZB-880 (torudokimab) with a goal of demonstrating their efficacy, safety, and dosing convenience in immune and inflammatory disorders, including systemic sclerosis, hidradenitis suppurativa, and other novel indications with unmet needs.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Upcoming Events
Sep 19, 2023 11:00 AM EDT
Nov 6 - Nov 7, 2023
Nov 28 - Nov 30, 2023